SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: shasta23 who wrote (20485)5/11/1998 5:44:00 PM
From: Peter Silsbee  Respond to of 32384
 
>> What happens now since they buy the company including the component?

The purchase of the company would not include any of LLY's rights to the drug. So this should not affect anything to do with the Lilly deal, except of course to finally resolve the question of which compound they choose. Chose.

PLS



To: shasta23 who wrote (20485)5/11/1998 5:46:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Stefan, As I recall, LGND could take the drug (DAB-IL2 )for cancer for $20 million, which is what they are doing. However the drug also has psoriasis applications which are not owned by LLY. SRGN also has additional cancer drugs. Thus, LGND is getting LLY's share (for $20 million), SRGN (for $67 million?), and the manufacturing plant (for $8 million). Part of the $67 million and all of the $20 million to LLY are contingent on FDA approval of DAB-IL2

That's my quick take. I'll post more soon.



To: shasta23 who wrote (20485)5/11/1998 7:16:00 PM
From: HerbertOtto  Read Replies (1) | Respond to of 32384
 
LGND gets new Cancer drug candidate!

Stefan, Since Henry has already responded, I'll go back to reading everybody else's posts. The next few weeks should be interesting.

I noticed Jim McCammet on CNBC this morning once again mentioned ISIP and not LGND. With all the activity in LGND this year I am surprised he did not mention LGND. Does anybody know if he has a political problem of some kind with LGND? I seem to remember Jim McCammet recommends LGND in his letter.

Good luck longs,
Herbert